Pfizer Inc. is an American multinational pharmaceutical corporation.
翻译：辉瑞公司是一家美国跨国制药企业。
Pfizer developed and produced the first FDA-approved COVID-19 vaccine in partnership with BioNTech.
翻译：辉瑞公司与BioNTech合作研发并生产了首款获得美国食品药品监督管理局（FDA）批准的COVID-19疫苗。
Pfizer's headquarters are located in New York City, United States.
翻译：辉瑞公司的总部位于美国纽约市。
The company
Pfizer has a long history of developing innovative medicines for various diseases.
翻译：辉瑞公司在开发治疗各种疾病的创新药物方面有着悠久的历史。
In 2020,
Pfizer made headlines with its highly effective coronavirus vaccine candidate.
翻译：2020年，辉瑞凭借其高度有效的冠状病毒疫苗候选产品登上了新闻头条。
Pfizer invests heavily in research and development to create breakthrough treatments for patients worldwide.
翻译：辉瑞大力投资于研究和开发，以创造出全球患者所需的突破性治疗方法。
Many of
Pfizer's drugs have become household names, such as Viagra used to treat erectile dysfunction.
翻译：辉瑞公司的许多药品已家喻户晓，如用于治疗勃起功能障碍的伟哥（Viagra）。
Pfizer employs over 80,000 people worldwide across multiple locations and subsidiaries.
翻译：辉瑞在全球各地及其子公司拥有超过8万名员工。
The merger between
Pfizer and Allergan was terminated in 2016 due to new U.S. Treasury rules.
翻译：由于新的美国财政部规定，辉瑞与艾尔建在2016年的合并计划被终止。
Pfizer is committed to improving access to healthcare in underserved communities around the world.
翻译：辉瑞致力于改善世界各地服务不足社区的医疗保健获取情况。
Volkswagen AG's chief executive visited China from late January to early February, the company said, while Apple CEO Tim Cook and Pfizer CEO Albert Bourla are expected to visit next month, people familiar with the matter told the Wall Street Journal.
知情人士告诉《华尔街日报》，大众汽车公司表示，该公司首席执行官于1月底至2月初访问了中国，而苹果首席执行官蒂姆·库克和辉瑞首席执行官阿尔伯特·波拉预计将于下月访问。
Top executives weighing a visit to the China Development Forum in Beijing include Apple CEO Tim Cook and Pfizer CEO Albert Bourla, people familiar with the matterxa0told the journal.
知情人士告诉《华尔街日报》，正在考虑访问北京中国发展高层论坛的高管包括苹果首席执行官蒂姆·库克和辉瑞首席执行官阿尔伯特·波拉。
"Jean-Christophe Pointeau, China president for Pfizer Global Biopharma Business, said the CIIE has proved to be a valuable platform for exhibition and communication to enhance joint efforts to optimize the public health and epidemic prevention system.
辉瑞全球生物制药业务中国区总裁Jean-Christophe Pointeau表示，事实证明，CIIE是一个宝贵的展览和交流平台，可以加强共同努力，优化公共卫生和防疫系统。
During last year's CIIE, Pfizer's antiviral oral therapeutic drug for COVID-19 Paxlovid made its debut in China.
在去年的CIIE期间，辉瑞公司针对新冠肺炎的抗病毒口服治疗药物奈玛特韦片/利托那韦片组合包装首次在中国上市。
The paper, compiled by the special committee, took an in-depth look at six companies - Pfizer, Siemens Healthineers, Johnson & Johnson, Abbott, BioMerieux and PerkinElmer - and how their investments, best practices, innovations, corporate social responsibility and strategic agendas in China can be used as a reference to enhance China's public health system.
这篇由特别委员会汇编的论文深入研究了辉瑞、西门子Healthineers、强生、雅培、BioMerieux和PerkinElmer六家公司，以及它们在中国的投资、最佳实践、创新、企业社会责任和战略议程如何作为加强中国公共卫生系统的参考。
Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis -- in China on Sunday.
周日，全球生物制药公司辉瑞在中国举行了Cibinqo的上市仪式。Cibinqo是一种口服的、每天一次的高选择性JAK1（Janus激酶1）抑制剂，用于治疗中重度特应性皮炎的成年患者。
Jean-Christophe Pointeau, president of China Pfizer Biopharmaceutical Group, said that Cibinqo is the group's globally ground-breaking innovative product in inflammation and immunology, and a crucial part of its dermatology strategic planning in China.
中国辉瑞生物制药集团总裁Jean-Christophe Pointeau表示，Cibinqo是该集团在炎症和免疫学领域的全球突破性创新产品，也是其在中国皮肤科战略规划的重要组成部分。
The launch of this inhibitor marks a globally synchronized R&D and regulatory application process and Pfizer's second breakthrough in Atopic dermatitis (AD) treatment.
该抑制剂的推出标志着全球同步的研发和监管应用程序，以及辉瑞在特应性皮炎（AD）治疗方面的第二次突破。
By further enriching the AD portfolio, Pfizer is set to meet the full range of treatment needs for AD patients with mild, moderate and severe atopic dermatitis.
通过进一步丰富AD产品组合，辉瑞将满足轻度、中度和重度特应性皮炎AD患者的全方位治疗需求。
As Pfizer's innovative targeted lung cancer therapy, the tablet demonstrates breakthrough in improving patients' progression-free survival, can better penetrate blood-brain barrier, and have less drug resistance, said the company.
辉瑞公司表示，作为其创新的靶向性癌症治疗方案，该片在提高患者无进展生存率方面取得了突破，可以更好地穿透血脑屏障，并减少耐药性。
"This innovative therapy is a great example of how Pfizer fulfills its mission to deliver 'breakthroughs that change patients' lives'," said Jean-Christophe Pointeau, president of Pfizer Biopharmaceuticals China.
辉瑞生物制药中国区总裁Jean-Christophe Pointeau表示：“这种创新疗法是一个很好的例子，说明辉瑞如何履行其使命，实现‘改变患者生活的突破’。”。
Zhao Jianjun, mayor of Wuxi, said at the online signing ceremony on Thursday that more than 1,200 industry giants, including AstraZeneca, Pfizer and Wuxi AppTec, have set up operations in the city, and that the industrial value of all biopharmaceutical companies in the city had reached 140.9 billion yuan ($21.4 billion) in 2021, up 20 percent year-on-year.
无锡市市长赵建军在周四的线上签约仪式上表示，包括阿斯利康、辉瑞和药明康德在内的1200多家行业巨头已在该市开展业务，2021年该市所有生物制药公司的工业价值达到1409亿元人民币（214亿美元），同比增长20%。
The Geneva-based Medicines Patent Pool's offer of a non-exclusive sublicense to several Chinese enterprises to produce the generic version of Pfizer's oral COVID-19 treatment can help mitigate poor access to COVID-19 medicines, industry experts and business leaders said on Friday, adding the offer is also a recognition of the Chinese makers' capability to produce high-quality drugs.
行业专家和商界领袖周五表示，基于基因的药物专利库向几家中国企业提供非排他性转授许可，以生产辉瑞口服新冠肺炎的仿制药，这有助于缓解新冠肺炎药物的获取困难，并补充说，这一提议也是对中国制造商生产高质量药物能力的认可。
According to the MPP, Pfizer will not receive royalties from sales of nirmatrelvir from the MPP sublicensees while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
根据MPP，在新冠肺炎仍被世界卫生组织列为国际关注的突发公共卫生事件期间，辉瑞公司将不会从MPP分许可证持有人处获得尼马特雷韦的销售特许权使用费。
The MPP sublicensing is the result of the voluntary licensing agreement signed by the MPP and Pfizer in November 2021.
MPP分许可是MPP和辉瑞于2021年11月签署的自愿许可协议的结果。
China Meheco Group Co Ltd signed an agreement with Pfizer Inc to supply the latter's COVID-19 treatment Paxlovid in the Chinese mainland in 2022, the company said Wednesday.
中国迈赫科集团有限公司周三表示，该公司与辉瑞公司签署协议，将于2022年在中国大陆供应后者的新冠肺炎治疗药物奈玛特韦片/利托那韦片组合包装。
Pfizer also confirmed the news on its official website and WeChat account.
辉瑞公司也在其官方网站和微信账号上证实了这一消息。
In February, the National Medical Products Administration, China's top drug regulator, gave conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral pill for the disease approved in the country.
今年2月，中国最高药品监管机构国家药品监督管理局有条件批准了辉瑞公司的新冠肺炎治疗药物奈玛特韦片/利托那韦片组合包装，使其成为中国批准的第一种口服药物。
AmCham China is a nonprofit, nongovernmental organization whose membership comprises 4,000 individuals from 900 companies, including Coca-Cola, Pfizer, Qualcomm, Honeywell, Walmart and Dell Technologies, operating across China.
中国美国商会是一个非营利的非政府组织，其成员包括来自900家公司的4000人，这些公司包括可口可乐、辉瑞、高通、霍尼韦尔、沃尔玛和戴尔技术公司，在中国各地开展业务。
Jean-Christophe Pointeau, president of Pfizer Biopharmaceuticals Group ChinaThe resilience and stability of China's market economy give us more confidence.
辉瑞生物制药集团中国总裁让-克里斯托夫·波因特中国市场经济的韧性和稳定性给了我们更多的信心。
Rooted in the Chinese market, Pfizer will consistently bring more innovative medical solutions to the Chinese people, and will not change this approach.
植根于中国市场，辉瑞将一如既往地为中国人民带来更多创新的医疗解决方案，而且不会改变这种做法。
For many foreign-invested companies, including Pfizer, it also lays a solid foundation to raise the confidence for long-term operations in China and the determination to actively integrate into China's economic development.
对于包括辉瑞在内的许多外商投资公司来说，这也为提高在中国长期经营的信心和积极融入中国经济发展的决心奠定了坚实的基础。
US pharmaceutical giant Pfizer is aiming to launch 24 first-in-class new therapies and new indications and drugs in China market by 2025 as part of efforts to contribute to the Healthy China 2030 Initiative, the company's top executive for China said on Thursday, the first day of the 4th China International Import Expo (CIIE).
美国制药巨头辉瑞公司中国区首席执行官周四，即第四届中国国际进口博览会的第一天表示，作为为“健康中国2030”倡议做出贡献的努力的一部分，该公司计划到2025年在中国市场推出24种一流的新疗法、新适应症和药物。
Jean-Christophe Pointeau, president of Pfizer Biopharmaceutical Group China, said that these new products will cover the fields of oncology, vaccines, anti-infectives, inflammation and immunology, and rare disease areas.
辉瑞生物制药集团中国区总裁Jean-Christophe Pointeau表示，这些新产品将覆盖肿瘤学、疫苗、抗感染、炎症和免疫学以及罕见病领域。
A restructuring of departments at Pfizer China will also take place to facilitate the launch of these products, he added.
他补充道，辉瑞中国公司还将对部门进行重组，以促进这些产品的推出。
"Pfizer is showcasing a wide range of products, including its latest breakthroughs, at the CIIE this year.
“辉瑞在今年的进博会上展示了一系列产品，包括其最新的突破。
United States-based pharmaceutical company Pfizer Inc supported the launch of China's first rheumatoid arthritis development report, in an effort to promote the country's RA diagnosis and treatment level.
美国制药公司辉瑞(Pfizer Inc.)支持发布了中国首份风湿性关节炎发展报告，以提升中国在该领域的诊断和治疗水平。
Felix Cao, chief medical officer and vice-president of Pfizer China, said: "At Pfizer, our purpose is breakthroughs that change patients' lives.
辉瑞中国首席医学官兼副总裁Cao Felix表示：“在辉瑞，我们的宗旨是创造能改变患者生活的突破性疗法。”
On April 9, 2020, BioNTech formed an agreement with Pfizer for the research and development of COVID-19 vaccine outside the Fosun territory.
2020年4月9日，BioNTech与辉瑞公司达成协议，共同研发COVID-19疫苗，但该合作不包括复星医药的区域。
BioNTech and Pfizer have signed orders of 1.4 billion doses for delivery this year.
BioNTech和辉瑞已经签署了今年交付14亿剂疫苗的订单。
The vaccine candidates, such as the messenger ribonucleic acid (mRNA) vaccine developed by US-based Pfizer and the recombination vaccine developed by UK-based AstraZeneca, had received orders for more than 1 billion doses overseas.
美国辉瑞公司研发的信使核糖核酸(mRNA)疫苗和英国阿斯利康公司研发的重组疫苗等候选疫苗已接到超过10亿剂的海外订单。
"Moderna was the second drugmaker to receive the FDA's emergency-use authorization approval for its coronavirus vaccine in the US after Pfizer BioNTech.
Moderna是继Pfizer-BioNTech之后，第二家获得美国FDA紧急使用授权批准其冠状病毒疫苗的制药公司。
Both Pfizer's and Moderna's vaccines require two doses.
辉瑞和Moderna的疫苗都需要两剂。
As the United States reported that the number of coronavirus patients in intensive care rose above 20,000 for the first time, there is hope that the Food and Drug Administration (FDA) will give emergency authorization to the Pfizer vaccine on Thursday, clearing the way for its almost-immediate distribution to all 50 states.
就在美国报告新冠患者进入重症监护室的人数首次超过2万人之际，人们寄希望于美国食品药品监督管理局(FDA)将在周四给予辉瑞(Pfizer)疫苗紧急授权，从而为该疫苗几乎立即分发至所有50个州铺平道路。
The Washington Post reported Monday that Pfizer has told the Trump administration it can't provide substantial additional doses of its vaccine until late June or July because other countries have bought up most of its supply, according to multiple individuals familiar with the situation.
《华盛顿邮报》周一报道，根据多位知情人士透露，辉瑞已告知特朗普政府，由于其他国家已经购买了该公司大部分疫苗供应，因此无法在6月底或7月之前提供大量额外疫苗。
Pfizer officials had urged the US to initially purchase 200 million doses, or enough for its two-shot regimen for 100 million people last summer, according to people knowledgeable about the issue who spoke on the condition of anonymity because they weren't authorized to discuss the situation.
据知情人士透露，去年夏天，辉瑞公司(Pfizer)的高管曾游说美国政府最初购买2亿剂疫苗，足够1亿人接种两针。这些人士不愿透露姓名，因为他们没有被授权讨论此事。
In a statement, Pfizer said that "the company is not able to comment on any confidential discussions that may be taking place with the US government".
辉瑞公司在一份声明中表示：“公司无法就可能与美国政府进行的任何机密讨论发表评论。”
"It's clear that Pfizer made plans with other countries.
很显然，辉瑞公司与其他国家制定了计划。
While US health authorities continue examining the proposed COVID-19 vaccines, in the UK, healthcare workers will begin inoculations of the Pfizer vaccine on Tuesday morning, aiming to vaccinate more than 20 million people in just a few months.
在美国卫生当局继续审查拟议中的COVID-19疫苗之际，英国的医疗工作者将于周二上午开始接种辉瑞疫苗，目标是在几个月内为2000多万人接种疫苗。
The first batch of the vaccine created by Pfizer and the German company BioNTech arrived in the UK last week.
上星期，第一批由辉瑞公司和德国BioNTech公司生产的疫苗抵达英国。
Bloomberg reported Monday that a spokesperson for the US Department of Health and Human Services (HHS) said states have used outdated federal estimates showing many more doses of Pfizer's vaccine would be available for the initial flow of shots.
Bloomberg周一报导，美国卫生与公众服务部(HHS)一位发言人表示，各州根据过时的联邦预估使用了更多辉瑞(Pfizer)疫苗剂量，这些预估表明初期注射疫苗的剂量将更多。
But more recently, federal officials have said that 6.4 million doses of the Pfizer vaccine and 12.5 million doses of the Moderna shots will be available in the first shipments.
但最近，联邦官员表示，首批运输中将有640万剂辉瑞疫苗和1250万剂Moderna疫苗可供使用。
That is 68 percent less than October estimates for Pfizer's vaccine and 17 percent less for Moderna.
这比10月份辉瑞疫苗的估计数量少了68%，比Moderna的估计数量少了17%。
For example, Pfizer signed a collaboration deal with the school of community medicine and public health at the Chinese Academy of Medical Sciences and Peking Union Medical College to raise public awareness of an enhanced public health system.
比如，辉瑞公司就与中国的中国医学科学院和北京协和医学院的社区医学与公共卫生学院签订合作协议，提升公众对强化公共卫生系统重要性的认识。
With a large population of children, China has huge demand for vaccines targeting pneumonia, and before the market launch of the domestic alternative, Pfizer's Prevnar 13, which was approved in China in 2016, was the only pneumococcal 13-valent conjugate vaccine available around the world.
Pfizer's sales for the vaccine came in at $5.8 billion in 2018, and the amounts of the vaccine released in China has grown quickly over the past few years, with 715,400 vials in 2017, 38.48 million vials in 2018 and 47.55 million vials in 2019, statistics from the company showed.
Also on Wednesday, US-based pharmaceutical company Pfizer signed three cooperation agreements, including those with the China Alliance of Rare Diseases and Microsoft Research, an institute specializing in basic and applied research, aiming to elevate the country's disease diagnosis and treatment standards in various disease areas.
"The collaboration with CARD is aimed at standardizing the medical treatment that rare disease patients can access in different regions and a better accessibility of drugs to ultimately improve their quality of life," said Wu Kun, Pfizer China Biopharma country lead.
Pfizer, a US-based pharmaceutical company, signed a collaboration agreement with the Boao Lecheng International Medical Tourism Pilot Zone in Hainan province at the ongoing China International Import Expo (CIIE) on Wednesday to accelerate introduction of innovative drugs into the zone and the country.
"It provides us with the opportunity to introduce our latest innovative therapies to the China market within the shortest time by reaching collaboration with the Lecheng pilot zone at the platform of CIIE," said Wu Kun, Pfizer China Biopharma country lead.
"Pfizer said China with a large population and a large number of middle class is currently the company's second-largest market in the world, and will continue to be a major market in its global blueprint as medical care and treatment is an important factor amid people's pursuit of a better life.
After receiving her PhD from the University of Cincinnati, she started her career with Pfizer Inc in the US in 1994.
After graduating from Jilin University in Northeast China’s Jilin province, Du went on to obtain her doctorate degree in biochemistry at the University of Cincinnati before joining world-leading pharmaceutical company Pfizer in 1994.
But Du was not content with what she had achieved at Pfizer.
In 2001, the Chinese American left Pfizer to set up Hutchison MediPharma and Hutchison China MediTech Limited which went public on the Nasdaq in 2016.
In 2012, he was appointed the CEO of the New Jersey-based company, whose previous avatar was Pfizer's animal health unit that was spun off.
Wu Xiaobin, president of Pfizer Greater China, always has ambitious goals not only for himself but for the company he leads.
Now, Pfizer China's dream is to raise the health condition of all the Chinese," said Wu, who is in charge of the Chinese mainland, Hong Kong and Taiwan business of Pfizer, one of the world's leading pharmaceutical companies.
Since his return in 1996, Wu has headed three largest international pharmaceutical enterprises in China (Bayer, Wyeth and Pfizer).
"Pfizer will associate with other companies and institutions to reduce the prevalence rate of chronic diseases among the Chinese, so that the latter could become a healthy people," Wu said, adding that the goal is far more difficult than any commercial competition.
"For a country's long-term steady development, its people's health should be up to the national strategy level," he said, stressing that Pfizer wants to be an essential part of China's healthcare system, and truly contribute to the society.
For this commitment, Pfizer China does a lot under the leadership of Wu, who said these efforts were far more meaningful than the simple sales growth.
In cooperation with the National Center for Cardiovascular Diseases, Pfizer China set up a grass-roots project last year to prevent cardiovascular diseases in rural areas through raising treatment level of doctors and relieving economic pressures of local patients.
"As an international enterprise, Pfizer also collects experiences and lessons of slow disease prevention and control from other countries, and provides useful reference material to Chinese institutions.
Since 1990s, Pfizer China has accumulated more than 200 million yuan in cash and kind in China, in response to natural disasters and various public welfare activities.
"As a company, our aim is to develop better instead of making money," said Wu, stressing that Pfizer aims to innovate continuously to bring patients drugs that can improve their health significantly.
With more than 10,000 employees, Pfizer China has cumulatively invested more than $1.5 billion in China, including setting up a research and development center and introducing internationally advanced production facilities in some factories.
By now, two third of the projects have been successfully implemented, including those initiated by Goodyear, Pfizer and Orix, Li said.
"And they mainly come from BASF, Exxon Mobil, Hyundai Motors, Siemens, Mitsubishi Electric, Procter & Gamble, Pfizer, Johnson & Johnson, Mitsubishi Corporation, Carlsberg, Golden Eagle Group, Chia Tai Group, Yazaki, ACWA Power of Saudi Arabia and related renowned companies," he said.
Minister Wang Wentao listened to information about the business operation of 12 foreign pharmaceutical firms such as Bayer, Novo Nordisk, Takeda Pharmaceuticals and Pfizer in China and solicited their demands and suggestions during the symposium.
"AmCham China is a nonprofit, nongovernmental organization whose membership comprises a large number of individuals from nearly 1,000 companies operating across China, including Coca-Cola, Pfizer, Qualcomm, Honeywell, Walmart and Dell Technologies.
As one of the companies that voiced its commitment to grow together with China, Pfizer said it looks forward to its new strategic partnership with the Healthy China Research Center, a Chinese research advisory platform, to advance the goals of Healthy China 2030 and other opportunities, according to Albert Bourla, the company's chairman and chief executive officer.
Albert Bourla, chairman and chief executive officer of US pharmaceutical company Pfizer, said that it will continue to work with key stakeholders in China to drive progress and promote innovations that will improve patients' lives.
In 2022, 11 new Pfizer drugs and indications were approved in China, and the company expects to submit up to 12 new drug applications in the country by 2025.
Volkswagen AG Chief Executive Oliver Blume visited China from late January to early February, while Apple CEO Tim Cook and Pfizer CEO Albert Bourla are expected to visit next month, The Wall Street Journal reported.
POINTEAU: China is the world's second-largest pharmaceutical market and an important market for Pfizer.
Pfizer remains committed in our efforts to drive key outcomes outlined in the Healthy China Initiative 2030 and will leverage our resources to introduce innovative drugs that benefit Chinese patients.
POINTEAU: Pfizer has confidence in the government's policies and efforts to optimize and attract foreign investment.
China is becoming an important source of innovation for Pfizer and the whole world.
Pfizer China R&D collaborates with leading academic and university institutions in China, and through these collaborations, we continue to advance the development of research and innovative medicines in China.
Pfizer中国研发中心与中国的顶尖学术和大学机构进行合作，通过这些合作，我们不断推动在中国的研究开发及创新药物的发展。
Advancing sustainable economic development is one of the key issues of global concern, and Pfizer is actively addressing climate change and pursuing a sustainable development path that supports and prioritizes our ESG (environmental, social and governance) related programs and commitments to long-term value creation, sustainability, and patient-first business models.
Pfizer's plants in China are resource-efficient and environmentally friendly, promoting an eco-civilized corporate development model.
POINTEAU: Pfizer is committed to supporting China's development paradigm to bring about a modernized and innovative approach whereby foreign enterprises strive for breakthroughs and contributions in scientific and technological innovation together with Chinese enterprises.
Jean-Christophe Pointeau, president of Pfizer Biopharmaceuticals Group China, said openness is of great significance to the current global environment that has been severely affected by the COVID-19 pandemic.
Jean-Christophe Pointeau, president of Pfizer Biopharmaceuticals Group China, said openness is of great significance to the current global environment which has been severely affected by the COVID-19 pandemic.
AmCham China is a nonprofit, nongovernmental organization whose membership comprises 4,000 individuals from nearly 1,000 companies, including Coca-Cola, Pfizer, Qualcomm, Honeywell, Walmart and Dell Technologies, operating across China.
"Lynn noted that the latest evidence suggests three doses of vaccine by the Chinese pharmaceutical company Sinovac are "at least as effective as the Pfizer and Moderna shots, and possibly even better for the over-80s, the most crucial sector of society to protect.
Pfizer has debuted many innovations at the previous CIIEs and will expand its presence at the fifth edition, said Jean-Christophe Pointeau, president of Pfizer Biopharmaceutical Group China, at the meeting.
Pfizer Inc and BioNTech SE last month asked US health regulators to allow their Covid-19 vaccine to be given to adolescents to extend their shot's use to children 12 years and older.
Nearly half of such agreements and joint projects were signed or carried out together with pharmaceutical MNCs, including AstraZeneca, Novartis, Pfizer and Omron.
Ever since China optimized its COVID-19 response in January, top executives of global pharmaceutical companies — US-based Pfizer, the United Kingdom's AstraZeneca, France's Sanofi and Germany's Bayer — have visited the country.
In June, Pfizer China announced that it will establish an innovation center in Hangzhou, Zhejiang province.
Jean-Christophe Pointeau, president of Pfizer China, said the innovation center aims to empower the healthcare industry in China with digital innovation and help solve industry challenges with mobile solutions.
Representatives from companies, including GE HealthCare, Novo Nordisk, Bayer, and Pfizer, attended the roundtable meeting with Chinese Commerce Minister Wang Wentao, according to an official statement.
The pharmaceuticals section, which is set to showcase innovative drugs, advanced technologies and services, has attracted the participation of leading pharmaceutical companies like Merck Sharp & Dohme, AstraZeneca, Pfizer, Roche, Sanofi and Takeda Pharmaceuticals, said Zhang.
Globally, US-based biopharmaceutical companies MSD and Pfizer started the research and development of COVID-19 oral drugs.
Shanghai Junshi Biosciences Co Ltd announced in January that a study led by Ruijin Hospital, an affiliate of the Shanghai Jiao Tong University School of Medicine, indicated that an oral antiviral drug co-developed with several domestic organizations for treating COVID-19 has a shorter time in sustained clinical recovery with fewer safety concerns compared with Paxlovid, the antiviral COVID-19 pill developed by United States-based Pfizer.
Jean-Christophe Pointeau, chairman of RDPAC Executive Committee and president of Pfizer Biopharmaceuticals Group China, said many pharmaceutical companies have been adopting business operation innovations and new collaboration modes with partners like medical institutions to ride the tide of internet and digital tools, under the background of regulatory reforms and new market conditions.
Before Walvax, US-based multinational company Pfizer was the only one in the world capable of producing PCV13 vaccines.
Pfizer's PCV13 version was approved in China in 2016 for children aged from six weeks to 15 months.
未经许可，严禁转发。QQ交流群：688169419